Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

References

• Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?. Int J Cancer 2013; 132:385 - 400; http://dx.doi.org/10.1002/ijc.27616; PMID: 22532371
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146:Suppl 61 1 - 6; http://dx.doi.org/10.1046/j.1365-2133.146.s61.2.x; PMID: 11966724
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27:2823 - 30; http://dx.doi.org/10.1200/JCO.2007.15.7636; PMID: 19349552
   PubMed Web of Science ®Google Scholar
• Kim C, Lee CW, Kovacic L, Shah A, Klasa R, Savage KJ. Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist 2010; 15:765 - 71; http://dx.doi.org/10.1634/theoncologist.2009-0237; PMID: 20538743
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158 - 66; PMID: 10623706
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, et al. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res 2009; 15:7711 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-09-2074; PMID: 19996224
   PubMed Web of Science ®Google Scholar
• Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change?. Cancer 2007; 109:455 - 64; http://dx.doi.org/10.1002/cncr.22427; PMID: 17200963
   PubMed Web of Science ®Google Scholar
• Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol 2008; 19:801 - 6; http://dx.doi.org/10.1093/annonc/mdm565; PMID: 18178958
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer 2008; 113:1632 - 40; http://dx.doi.org/10.1002/cncr.23791; PMID: 18720480
   PubMed Web of Science ®Google Scholar
• Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 2009; 8:493 - 9; http://dx.doi.org/10.1517/14740330902918281; PMID: 19435405
   PubMed Web of Science ®Google Scholar
• Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22:610 - 6; http://dx.doi.org/10.1200/JCO.2004.07.060; PMID: 14726505
   PubMed Web of Science ®Google Scholar
• Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008; 26:2299 - 304; http://dx.doi.org/10.1200/JCO.2007.14.5292; PMID: 18467721
   PubMed Web of Science ®Google Scholar
• Gajewski TF. Cancer immunotherapy. Mol Oncol 2012; 6:242 - 50; http://dx.doi.org/10.1016/j.molonc.2012.01.002; PMID: 22248437
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295 - 307; http://dx.doi.org/10.1038/nri1806; PMID: 16557261
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116; PMID: 21498393
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002; 95:389 - 96; http://dx.doi.org/10.1002/cncr.10663; PMID: 12124839
   PubMed Web of Science ®Google Scholar
• Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, et al. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 1993; 72:607 - 14; http://dx.doi.org/10.1002/1097-0142(19930715)72:2<607::AID-CNCR2820720245>3.0.CO;2-R; PMID: 8319195
   PubMed Web of Science ®Google Scholar
• Harvey Motulsky. 2012. GraphPad Prism, Version 5.0. In Statistical analyses for laboratory and clinical researchers.
   Google Scholar
• Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rötzschke O, et al. CD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cells. Blood 2009; 113:827 - 36; http://dx.doi.org/10.1182/blood-2008-04-150524; PMID: 18941119
   PubMed Web of Science ®Google Scholar
• Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011; 118:2254 - 65; http://dx.doi.org/10.1182/blood-2010-12-325753; PMID: 21734236
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745 - 63; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104702; PMID: 15032595
   PubMed Web of Science ®Google Scholar
• Andersen RS, Kvistborg P, Frøsig TM, Pedersen NW, Lyngaa R, Bakker AH, et al. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 2012; 7:891 - 902; http://dx.doi.org/10.1038/nprot.2012.037; PMID: 22498709
   PubMed Web of Science ®Google Scholar
• Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012; 72:1642 - 50; http://dx.doi.org/10.1158/0008-5472.CAN-11-2614; PMID: 22311675
   PubMed Web of Science ®Google Scholar
• Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009; 6:520 - 6; http://dx.doi.org/10.1038/nmeth.1345; PMID: 19543285
   PubMed Web of Science ®Google Scholar
• Vestermark LW, Holtved E, Dahlrot R, Brimnes MK, Svane IM, Bastholt L. A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response. Ecancermedicalscience 2008; 2:91; PMID: 22275974
   PubMedGoogle Scholar
• Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623 - 33; http://dx.doi.org/10.1172/JCI25947; PMID: 16308572
   PubMed Web of Science ®Google Scholar
• Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008; 6:12; http://dx.doi.org/10.1186/1479-5876-6-12; PMID: 18334033
   PubMed Web of Science ®Google Scholar
• Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J 2010; 16:342 - 7; http://dx.doi.org/10.1097/PPO.0b013e3181eb336d; PMID: 20693845
   PubMed Web of Science ®Google Scholar
• Engell-Noerregaard L, Ellebæk E, Iversen TZ, Hansen TH, Brimnes MK, Met O, et al. Analysis of regulatory T cell phenotype, including CD49d, during treatment of melanoma patients with dendritic cell vaccine, Interleukine-2 and/or metronomic Cyclophosphamide. Clinical and Cellular Immunology 2011; In press
   Google Scholar
• Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012; 1:409 - 18; http://dx.doi.org/10.4161/onci.18851; PMID: 22754759
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Rech AJ, Mick R, Kaplan DE, Chang KM, Domchek SM, Vonderheide RH. Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2010; 59:599 - 607; http://dx.doi.org/10.1007/s00262-009-0780-x; PMID: 19855964
   PubMed Web of Science ®Google Scholar
• Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35:107 - 15; http://dx.doi.org/10.1097/CJI.0b013e318242169f; PMID: 22306898
   PubMed Web of Science ®Google Scholar
• Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother 2010; 33:817 - 27; http://dx.doi.org/10.1097/CJI.0b013e3181ecccad; PMID: 20842055
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18:555 - 67; http://dx.doi.org/10.1158/1078-0432.CCR-11-1491; PMID: 22048237
   PubMed Web of Science ®Google Scholar
• Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17:4568 - 80; http://dx.doi.org/10.1158/1078-0432.CCR-11-0184; PMID: 21586625
   PubMed Web of Science ®Google Scholar
• Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 2006; 1:1120 - 32; http://dx.doi.org/10.1038/nprot.2006.121; PMID: 17406393
   PubMed Web of Science ®Google Scholar